High-dose weekly liposomal amphotericin B antifungal prophylaxis in patients undergoing liver transplantation: A prospective phase II trial

Transplantation

Volumn 99, Issue 4, 2015, Pages 848-854

  Giannella, Maddalena ^a   Ercolani, Giorgio ^b   Cristini, Francesco ^a   Morelli, Mariacristina ^b   Bartoletti, Michele ^a   Bertuzzo, Valentina ^b   Tedeschi, Sara ^a   Faenza, Stefano ^b   Puggioli, Cristina ^a   Lewis, Russell E ^a   Pinna, Antonio Daniele ^b   Viale, Pierluigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; IMMUNOSUPPRESSIVE AGENT; AMPHOTERICIN B; ANTIFUNGAL AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; HOSPITAL DISCHARGE; HUMAN; HYPOKALEMIA; INCIDENCE; INFUSION RELATED REACTION; INVASIVE CANDIDIASIS; KIDNEY INJURY; LIVER TRANSPLANTATION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC MYCOSIS; THORAX PAIN; TREATMENT DURATION; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG ADMINISTRATION; ITALY; MICROBIOLOGY; MIDDLE AGED; MYCOSES; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITALY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930166371     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000393     Document Type: Article

References (31)

1. Cruciani M, Mengoli C, Malena M, et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12:850.
2. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis. 2004;39(Suppl 4):S200.
3. Silveira FP, Kusne S. Candida infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):220.
4. Singh N, Husain S. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):228.
5. Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87:424.
6. Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant recipients. Liver Transpl. 2012;18:680.
7. Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2013;96:573.
8. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010;35:211.
9. Chan TS, Gill H, Hwang YY, et al. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Ann Hematol. 2013;93:493.
10. Pang KA, Godet C, Fekkar A, et al. Breakthrough invasive mould infections in patients treated with caspofungin. J Infect. 2012;64:424.
11. Fekkar A, Meyer I, Brossas JY, et al. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother. 2013;57:2380.
12. Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect. 2008;14(Suppl 4):55.
13. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45:922.
14. Lewis RE, Albert ND, Kontoyiannis DP. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2008;52:4178.
15. Gubbins PO, Amsden JR, McConnell SA, et al. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) inperipheral stem cell transplant patients. Antimicrob Agents Chemother. 2009;53:3664.
16. Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12:235.
17. El-Cheikh J, Faucher C, Furst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:301.
18. Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents. 2008;31:135.
19. Ellis M, Bernsen R, Ali-Zadeh H, et al. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J Med Microbiol. 2009;58(Pt 11):1474.
20. Ginocchio F, Faraci M, Fioredda F, et al. Weekly high-dose liposomal amphotericin B for secondary prophylaxis of invasive fungal disease in immunocompromised children: experience from a pediatric case series. J Chemother. 2012;24:243.
21. Annino L, Chierichini A, Anaclerico B, et al. Prospective phase II singlecenter study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother. 2013;57:2596.
22. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother. 2003;52:813.
23. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008.
24. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17:113, viii.
25. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101.
26. van Hal SJ, Marriott DJ, Chen SC, et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis. 2009;11:122.
27. Lafaurie M, Lapalu J, Raffoux E, et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect. 2010;16:1191.
28. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487.
29. DCTD N, NIH, DHHS Cancer Therapy. Common Toxicity Criteria Version 2.0. Cancer Therapy Evaluation Program. 1998;March.
30. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813.
31. O'Riordan A, Wong V, McQuillan R, et al. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant. 2007;7:168.